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Abstract Diabetes mellitus (DM) is a lifelong progressive
disease. Currently there are more than 285 million DM-
affected people worldwide. Globally the prevalence of
diabetes continues to rise and is more pronounced in
countries with large populations such as China, India and
USA. Driving forces behind the epidemic are obesity, aging
of the population and longer life expency. Prospective, the
majority of diabetic population will be in their six to eight
decades of life with the implication of more females than
males. Severe micro- and macrovascular complications
associated with diabetes lead to a highly increased
morbidity and mortality. Therefore, DM is projected to be
one of the leading health problems of 21st centuary. Urgent
measures are required to reduce the diabetic burden. Thus
advanced predictive diagnostic tools and personalized
treatment strategies in (pre)diabetic care are critical and
should exert beneficial impact on public health.
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Global prevalence of Diabetes mellitus
Diabetes mellitus (DM) is a lifelong progressive disease. It
is classified as a group of heterogeneous metabolic
disorders characterized by hyperglycemia as a common
feature. The vast majority cases of DM fall mainly into two
broad etiopathogenetic categories, classified as type 1 and
type 2 DM. Type 1 DM is induced by beta cell destruction,
whereas pancreatic beta cell dysfunction and insulin
resistance are hallmark features of type 2 DM.
A number of factors are known to impact the disease
development. Genetic predisposition, is well-acknowledged
for both types of DM [1]. Further factors can be
summarized as environmental influence, life style, in-
creased stress, nutritional behaviors, such as frequent fast
food consumption, and low physical activity. As a
consequence, the number of diabetic patients is continu-
ously increasing worldwide.
The prevalence of DM has already achieved epidemic
proportion with more than 285 million patients worldwide
[2]. Statistically, DM-affected patients comprise almost
6.4% of the world’s population [3]. The incidence of type
1 DM accounts for 5–10% of all new DM diagnoses, while
the dominating type 2 DM accounts for 90–95% of all
cases worldwide [4].
Diabetes prevalence will more than double over the next
30 years and is projected to rise from 4.4% in 2000 to 7.7%
in 2030. Consequently, the worldwide prevalence of
diabetes amoung adults (20–79 years of age) is expected
to increase up to about 439 million by the year 2030 [3].
The projections for DM prevalence are becoming more
pessimistic year by year (see Fig. 1).
Main contributing factors can be summarized as aging of
the population, urbanization, increasing prevalence of
obesity and low physical activity etc. [5–9]. The increased
prevalence of DM is predicted to occur virtually for every
nation, while the greatest increase is expected in developing
countries [10, 13]. In developed countries, the prevalence
of DM has been shown to be similar in urban and rural
areas. In contrast, significantly higher DM prevalence
occurs in the urban population of developing countries,
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which may relate to factors such as unbalanced diet,
obesity, decreased physical activity and stress [10]. The
prospective estimates are that from 2010 to 2030, there will
be an increase of 69% in the number of adult diabetic
pateints for the developing countries, while for developed
countries it is expected to increase by 20% [3].
According to NIDDK (National Institute of Diabetes and
Digestive and Kidney Diseases), people of African-
Caribbean, Asian, and Hispanic origin are more frequently
affected by the disease [14]. Furthermore, prognosis for the
year 2030 is demonstrating that countries with high
population numbers, such as China, India and USA, will
have a bigger increase in both absolute number and
percentage of DM cases in population (see Fig. 2).
Worldwide, India has the highest absolute number regis-
tered for diabetic patients in 2010. The estimated DM
population is 50.8 million, while the projection for the
future is rising up to 87 million DM-affected people for
2030 [3]. In Europe Germany is listed among top ten
countries having the highest estimated number of diabetics
in the world [15, 16].
Impact of aging, education and socioeconomic status
on DM prevalence
Aging is one of the major factors promoting the
epidemic scale of DM [17]. Currently diabetes is seen
to be highly prevalenced in the two age groups of 40–59
and 60–79 years with 131 and 108 million affected
individuals, respectively (see Fig. 3). By 2030, it is
predicted that there will be 188 million people with
diabetes aged 40–59 years and considerably even more
people in the age group over 60 years old, estimated to be
about 196 million [2]. In addition, both industrialization
and globalization affect the rising prevalence of diabetes
in the younger age categories including teenagers [18].
In most countries, a lower educational level was
associated with higher prevalence of diabetes compared to
better educated groups. In western countries, the risk for
developing diabetes is strongly linked to a low socioeco-
nomic status. Most of the studies have shown that people
with higher socioeconomic position have a low prevalence
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Fig. 1 Global prevalence of
diabetes mellitus (DM) for the
years 1995–2030. Total DM-
affected population is projected
to rise from 285 million in 2010
to 439 million in 2030. World-
wide, a strong increase in
diabetic burden is predicted,
particularly starting from the








































Fig. 2 Top six countries with
highest DM-affected population
between 20–79 years of age in
2010 and 2030 [2]. India has the
largest DM prevalence, with
the growth rate percentage of
71.3%, followed by China
(44.9%), USA (34.3%) and
Russia (7.3%). For Germany
and Japan the prevalence data
for the year 2030 are currently
not available
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have a higher prevalence of the disease [9, 19–22]. Further,
the influence of socioeconomic factors on DM prevalence
has been shown to be higher among women compared to
men.
Gender aspect in DM-Prevalence
Eventhough global prevalence of Diabetes mellitus is
similar in men and women (see Fig. 4), it has been
demonstrated that age plays a major role in gender
prevalence. In the age above 65 years, diabetes tends to
be more frequent in women than men [10, 23].
Prevalence of DM-associated complications
and mortality
Chronic complications, secondary to diabetes are affecting
many organ systems, being responsible for a considerably
shortened life-expectancy and sudden death (see Fig. 5a and b).
Specific complications of diabetes depend on many factors
including the duration of the metabolic derangements.
Microvascular complications, due to damage to small
blood vessels, are involved in the pathomechanisms of all
chronic DM-related pathologies. Diabetic neuropathy is the
leading DM-associated complication. Peripheral sensory
neuropathy is the most common form of diabetic neurop-
athy affecting 40–50% of patients with diabetes [27]. It
mainly affects the feet, leading to foot lesions, numbness
and foot/toe amputation. Diabetic retinopathy, the earliest
manifestation of organ damage developed in DM popula-
tion, is the second most common complication (see
Fig. 5a). In diabetic patients, nephropathy is the main risk
factor for all cardiovascular mortalities [28]. Recent studies
in the United States implicate chronic nephropathy as the
leading cause of renal failure. It is affecting also up to 40%
of patients with diabetes worldwide [29].
Macrovascular complications, which relate to the heart
and large blood vessels, are peripheral vascular diseases,
coronary artery diseases, arthrosclerosis and stroke [30].
Cancer provocation in diabetes Recent research shows
that diabetic patients are generally predisposed to cancer
[31, 32].
Mortality Worldwide every 10 s a person dies due to a
diabetes-related pathology. Furthermore, DM is docu-
mented to be the fourth leading cause of death. In the year
2010, the global mortality attributed to diabetes was
estimated to be 3.96 million, showing an increase of 5.5%
when compared to the mortality in the year 2007 [23]. The
percentage of all death in the diabetic population between
20–79 years of age was lowest (6%) in the poorest African
countries and highest in the North American region
(15.7%) (see Fig. 6). Doubling of the population will be
the main reason for the global burden of diabetes in the
next 25 years [33]. The highest number of deaths due to
diabetes is projected to occur in countries with large
populations such as China, India, USA and the Russian
Federation. More women than men are expected to die from
diabetes-related complications, thus diabetes contributes

































Fig. 4 Global prevalence of diabetes in men and women aged
between 20–79 years, estimated for the years 2003–2030 [2, 23, 24].
Currently, there are 6.6% people with diabetes mellitus worldwide;
143 million of them are women and 142 million are men.
Prospectively, the prevalence of DM will continue to increase. For
2030, it is expected that there will be about 6 million more women
























Fig. 3 Global DM prevalence in different age groups for the years
2010 and 2030 [2]. Current DM prevalence is likely to be largest
among the age group of 40–59 years with 132 million people,
followed by the age group of 60–79 years with 108 million. In 2030,
an increase is expected in all age groups, with greatest number of
people in the 60–79 years of life. Estimates indicate an increase of 88
million and 56 million for the age groups of 60–79 years and 40–
59 years, respectively
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The percentage of excess deaths due to diabetes was
highest in people 55–59 years old, currently having the
largest effect in South-East Asia (see Fig. 7). When
comparing similar age groups of DM-affected versus
general population, the annual mortality rate has been
documented to be two-fold higher in diabetic patients. Each
year nearly 3 million people die because of diabetes, and
two thirds of them die in developing countries [33].
Conclusions
According to the information provided above, we conclude:
– DM micro- and macrovascular complications are one
of the leading health problems of 21st century.
– Over the next 20 years, DM-affected population is
likely to be increase by 50%.
– Although prevalence of diabetes continues to rise in every
nation, the highest increase is expected to occur in
countries with large populations – China, India and USA.
– Urban population in developing countries is projected
to double which will likely lead to increased diabetic
prevalence.
– Most important demographic change in DM prevalence
across the world appears to be the increase in older
population (age above 60 years), as a consequence of
longer life span.
– DM is more frequent in females than males.
– The progressive prevalence of DM will lead to a very
high economic burden.
– Severe complications lead to highly increased morbidity
and mortality among DM patients. Global excess mortal-
ity due to diabetes is more pronounced in developing
countries and individuals with low socioeconomic status.
Urgent measures should be considered:
– Early prevention of DM in childhood and adults
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Fig. 6 Worldwide documented DM-associated mortality for the
population aged between 20–79 years in contest of regional differ-
ences as updated for 2010 [23]. Diabetes accounted for over 1 in 20
deaths. Total percentage of diabetic mortality is very high particularly

































a India b USA 
Fig. 5 a. Prevalence of type 2 DM micro- and macrovascular
complications, in percentage, for Indian population during the year
2000. Among microvascular complications, nephropathy (32.5%) is
the most frequent followed by neuropathy and retinopathy with 30.1%
and 28.9%, respectively. Among macrovascular complications, car-
diovascular complications are more common and hypertension is
significantly associated with all complications [25]. b. Prevalence of
type 2 DM complications, in percentage, for USA, from NHANES
(National Health and Nutrition Examination Survey) for the years
1999–2004 [26]. Nephropathy is one of the major microvascular
complications, with the prevalence of 25% followed by foot problems
and eye damage. Heart disease are prevalent common among macro-
vascular complications
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– Application of advanced predictive diagnostics to
preventively treat individuals at high risk
– Personalized treatment in (pre)diabetes
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Fig. 7 Number of deaths (in thousands) attributable to diabetes by
age groups and gender. Global mortality was lowest in the Eastern
Mediteran and Africa regions, while the highest numbers were
documented in South-East Asia and America. DM-associated deaths
are particularly increased for the age group of 35–64 years, in regions
where the prevalence of diabetes is very high in younger ages (South
East Asia, America and Africa). In Europe, DM mortality tends to be
more frequent in men than in women. On the other hand, for all other
regions, the prevalence of DM mortality is higher in female
population, mainly in the age group older than 64 years. Among the
younger age group of 0–34 years, the numbers of deaths were high in
South-East Asia (29.1 thousand men and 33.1 thousand women) and
Africa (20 thousand men and 32.2 thousand women) [33]
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